文献速递MDS 与骨髓增殖性肿瘤贫血与红细胞疾病

Imetelstat 在高输血负荷低危 MDS Ⅱ期研究中的疗效与安全性

Imetelstat Achieves Meaningful and Durable Transfusion Independence in High Transfusion-Burden Patients With Lower-Risk Myelodysplastic Syndromes in a Phase II Study.
PubMed 文献 · J Clin Oncol · 2020-10-27

该Ⅱ期研究评估端粒酶抑制剂 Imetelstat 在红细胞输注依赖且对 ESA 复发/难治的低危 MDS 患者中的疗效。总体人群 8 周和 24 周 RBC 输血独立率分别为 37% 和 23%,中位 TI 持续时间 65 周;亚组人群分别为 42% 和 29%,中位 TI 持续时间 86 周。细胞遗传学和突变数据显示恶性克隆减少,提示疾病修饰活性。

要点

  • Imetelstat 在高输血负荷低危 MDS 中产生有意义且持久的输血独立。
  • 总体人群 8 周 TI 率 37%,24 周 TI 率 23%,中位 TI 65 周。
  • 最常见不良事件为血细胞减少,通常 4 周内可逆。

核心结论

  • Imetelstat 在不可用或复发/难治于 ESA 的高输血低危 MDS 患者中产生有意义且持久的输血独立。
  • 生物标志物分析提示 Imetelstat 对突变恶性克隆有抑制作用。

研究设计与样本

  • Ⅱ/Ⅲ期研究 MDS3001 的Ⅱ期部分,报告 57 例入组并治疗患者的疗效、安全性和生物标志物数据。
  • 总体人群 57 例,其中 38 例为非 del(5q) 且未接受过低甲基化药物和来那度胺的亚组人群。

主要发现

  • 总体人群 8 周和 24 周 RBC 输血独立率分别为 37% 和 23%,中位 TI 持续时间 65 周。
  • 亚组人群 8 周和 24 周 RBC 输血独立率分别为 42% 和 29%,中位 TI 持续时间 86 周。
  • 所有评估亚组均观察到 8 周 TI 率。
  • 细胞遗传学和突变数据显示恶性克隆减少,提示疾病修饰活性。
  • 最常见不良事件为血细胞减少,通常在 4 周内可逆。

关键数值与推荐

  • 主要终点为 8 周 RBC 输血独立率,关键次要终点包括 24 周 RBC TI 率、TI 持续时间和红系血液学改善。

临床怎么用

  • 对于红细胞输注依赖且对 ESA 复发/难治的低危 MDS 患者,Imetelstat 可考虑作为治疗选择以追求输血独立。
  • 治疗期间需监测血细胞减少,但通常可逆。

局限性

  • 本文报告的是Ⅱ期部分数据,样本量有限。
  • Ⅲ期部分结果尚未报告。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Patients with lower-risk (LR) myelodysplastic syndromes (MDS) who are RBC transfusion dependent and have experienced relapse after or are refractory to erythropoiesis-stimulating agent (ESA) have limited treatment options. High telomerase activity and human telomerase reverse-transcription expression in clonal hematopoietic cells have been reported in patients with MDS. Imetelstat, a first-in-class competitive inhibitor of telomerase enzymatic activity, targets cells with active telomerase. We report efficacy, safety, and biomarker data for patients with LR MDS who are RBC transfusion dependent and who were relapsed/refractory to ESAs. PATIENTS AND METHODS: In this two-part phase II/III study (MDS3001), the primary end point was 8-week RBC transfusion independence (TI) rate, with key secondary end points of 24-week RBC TI rate, TI duration, and hematologic improvement-erythroid. RESULTS: Data from the phase II part of the study are reported. Of 57 patients enrolled and treated (overall population), 38 were non-del(5q) and hypomethylating agent and lenalidomide naïve (subset population). The 8- and 24-week RBC TI rates in the overall population were 37% and 23%, respectively, with a median TI duration of 65 weeks. In the subset population, 8- and 24-week RBC TI rates were 42% and 29%, respectively, with a median TI duration of 86 weeks. Eight-week TI rate was observed across all subgroups evaluated. Cytogenetic and mutational data revealed a reduction of the malignant clones, suggesting disease modification activity. The most common adverse events were cytopenias, typically reversible within 4 weeks. CONCLUSION: Imetelstat treatment results in a meaningful, durable TI rate across a broad range of heavily transfused patients with LR MDS who are ineligible for or relapsed/refractory to ESAs. Biomarker analyses indicated effects on the mutant malignant clone.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Steensma DP, Fenaux P, Van Eygen K, et al. Imetelstat Achieves Meaningful and Durable Transfusion Independence in High Transfusion-Burden Patients With Lower-Risk Myelodysplastic Syndromes in a Phase II Study. J Clin Oncol. 2020. PMID: 33108243. doi:10.1200/JCO.20.01895

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。